BİLİCİ, A. Et Al. 2023. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study. ACTA ONCOLOGICA , vol.62, no.4 , 381-390.

BİLİCİ, A., ÖLMEZ, Ö. F., Kaplan, M. A., Oksuzoglu, B., Sezer, A., Karadurmus, N., ... ÇUBUKÇU, E.(2023). Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study. ACTA ONCOLOGICA , vol.62, no.4, 381-390.

BİLİCİ, Ahmet Et Al. "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study," ACTA ONCOLOGICA , vol.62, no.4, 381-390, 2023

BİLİCİ, Ahmet Et Al. "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study." ACTA ONCOLOGICA , vol.62, no.4, pp.381-390, 2023

BİLİCİ, A. Et Al. (2023) . "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study." ACTA ONCOLOGICA , vol.62, no.4, pp.381-390.

@article{article, author={Ahmet BİLİCİ Et Al. }, title={Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study}, journal={ACTA ONCOLOGICA}, year=2023, pages={381-390} }